financetom
Market
financetom
/
Market
/
Top brokerage calls for June 17: CLSA bullish on ITC but cuts TP, Morgan Stanley 'underweight' on Hexaware
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Top brokerage calls for June 17: CLSA bullish on ITC but cuts TP, Morgan Stanley 'underweight' on Hexaware
Jun 16, 2019 11:44 PM

Top brokerage calls for June 17: CLSA bullish on ITC but cuts TP, Morgan Stanley 'underweight' on Hexaware

SUMMARY

India benchmark indices are set for a muted start on Monday as concerns of rising oil prices and delayed monsoon weigh on the economy. Asian shares also traded flat ahead of the monetary policy decision of the US Federal Reserve on June 19. Among brokerages, CLSA remains positive on ITC but cuts its target price. While Credit Suisse has an 'underperform rating for Dr Reddy's and 'neutral' call on Sun Pharma. Morgan Stanley is 'overweight' on Biocon and 'underweight on Hexaware. Here are the top brokerage calls for Monday:

By CNBC-TV18Jun 17, 2019 8:44:14 AM IST (Published)

CLSA on ITC: The brokerage maintains 'buy' target on the stock but reduces its target price to Rs 365 per share from Rs 400 earlier. Risk-reward attractive, but target cut on a lower cigarette multiple, the brokerage added.

Morgan Stanley on Hexaware: The brokerage is 'underweight; on the stock with the target at Rs 350 per share. Revenue synergies will be key to watch as margin upside is limited, it added.

Credit Suisse on Dr Reddy's: The brokerage retains 'underperform' rating for the stock with a target at Rs 2,415 per share. It expects 3 filings from the company in 2019.

Morgan Stanley on Biocon: The brokerage maintains 'overweight' call on Biocon, expects sales momentum to continue with biosimilar business.

Credit Suisse on Sun Pharma: The brokerage maintains a 'neutral' call on Sun Pharma after the company's second phase study on Illumya.

Citi on JSPL: The brokerage is bullish on the stock with the target at Rs 250 per share. Valuation of the stock remains cheap with significant growth in cash flows and fast deleveraging, it added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Financial
Sector Update: Financial
Mar 21, 2024
03:19 PM EDT, 03/21/2024 (MT Newswires) -- Financial stocks advanced late Thursday afternoon, with the NYSE Financial Index and the Financial Select Sector SPDR Fund (XLF) each rising 0.9%. The Philadelphia Housing Index climbed 1.8%, and the Real Estate Select Sector SPDR Fund (XLRE) was adding 0.4% Bitcoin (BTC-USD) dropped 4% to $65,176, and the yield for 10-year US Treasuries...
Nike warns of revenue dip as it cuts back on key products
Nike warns of revenue dip as it cuts back on key products
Mar 21, 2024
(Reuters) -Nike ( NKE ) warned on Thursday that its revenue in the first half of fiscal 2025 would shrink by a low single-digit percentage as the world's largest sportswear maker scales back on franchises to save costs. Nike's ( NKE ) warning came after the stock market closed, and shares were down about 6% in extended trading. Executives acknowledged...
Nike expects first half of fiscal 2025 to be pressured as it cuts supply of key products
Nike expects first half of fiscal 2025 to be pressured as it cuts supply of key products
Mar 21, 2024
March 21 (Reuters) - Nike ( NKE ) warned on Thursday that its revenue in the first half of fiscal 2025 would shrink by a low single-digit percentage as the world's largest sportswear maker scales back on franchises to save costs. Nike's ( NKE ) warning came after the stock market closed, and shares were down 5.6% in extended trading....
Sector Update: Health Care
Sector Update: Health Care
Mar 21, 2024
03:42 PM EDT, 03/21/2024 (MT Newswires) -- Health care stocks rose late Thursday afternoon with the NYSE Health Care Index adding 0.2% and the Health Care Select Sector SPDR Fund (XLV) rising 0.3%. The iShares Biotechnology ETF (IBB) climbed 0.9%. In corporate news, Eledon Pharmaceuticals ( ELDN ) shares surged 12% after it said its tegoprubart monoclonal antibody was used...
Copyright 2023-2026 - www.financetom.com All Rights Reserved